Literature DB >> 16822903

Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency.

José A Borghans1, Robbert G Bredius, Mette D Hazenberg, Helene Roelofs, Els C Jol-van der Zijde, Jeroen Heidt, Sigrid A Otto, Taco W Kuijpers, Willem E Fibbe, Jaak M Vossen, Frank Miedema, Maarten J van Tol.   

Abstract

The immune system of patients with severe combined immunodeficiency (SCID) reconstitutes to a large extent during the first years after hematopoietic stem cell transplantation (HSCT). It was suggested, however, that accelerated loss of thymus output may cause impaired immune function at the long term. To address this issue, we studied patients with SCID who underwent allogeneic HSCT 5 to 32 years earlier and identified early determinants of long-term T-cell reconstitution. A variety of immune parameters were analyzed both early (1-4 years) and late (5-32 years) after HSCT. Late after HSCT, a clear distinction could be made between a group of 8 patients with impaired T-cell reconstitution and 11 patients with good immune reconstitution. Importantly, in patients with decreased long-term T-cell reconstitution, T-cell recovery was already poor early after HSCT, demonstrating that long-term immune failure was not caused by accelerated loss of thymus output or long-term graft failure, but resulted from poor early grafting. The number of T-cell receptor excision circles (TRECs) early after HSCT was most predictive for long-term T-cell reconstitution. Frequent monitoring of T-cell immunity and TREC numbers early after HSCT may thus serve to timely identify patients who will fail to reconstitute properly and who may need additional treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16822903     DOI: 10.1182/blood-2006-01-009241

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Partial depletion of TCR alpha/beta(+)/ CD19(+) cells in matched unrelated transplantation of three patients with osteopetrosis.

Authors:  F Porta; S Cavagnini; L Imberti; A Sottini; F Bolda; A Beghin; A Caruso; A Lanfranchi
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

2.  T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/βTREC ratio and thymic naive T cells.

Authors:  Simone Ringhoffer; Markus Rojewski; Hartmut Döhner; Donald Bunjes; Mark Ringhoffer
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 3.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.

Authors:  Jennifer Heimall; Jennifer Puck; Rebecca Buckley; Thomas A Fleisher; Andrew R Gennery; Benedicte Neven; Mary Slatter; Elie Haddad; Luigi D Notarangelo; K Scott Baker; Andrew C Dietz; Christine Duncan; Michael A Pulsipher; Mort J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-06       Impact factor: 5.742

Review 4.  Long term outcomes of severe combined immunodeficiency: therapy implications.

Authors:  Jennifer Heimall; Morton J Cowan
Journal:  Expert Rev Clin Immunol       Date:  2017-09-23       Impact factor: 4.473

5.  Clonotypic analysis of T cell reconstitution after haematopoietic stem cell transplantation (HSCT) in patients with severe combined immunodeficiency.

Authors:  H Okamoto; C Arii; F Shibata; T Toma; T Wada; M Inoue; Y Tone; Y Kasahara; S Koizumi; Y Kamachi; Y Ishida; J Inagaki; M Kato; T Morio; A Yachie
Journal:  Clin Exp Immunol       Date:  2007-03-21       Impact factor: 4.330

6.  The long and the short of telomeres in bone marrow recipient SCID patients.

Authors:  Marcella Sarzotti-Kelsoe; Xiaoju G Daniell; John F Whitesides; Rebecca H Buckley
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 7.  Hematopoietic stem cell transplantation for primary immunodeficiencies.

Authors:  Elizabeth Kang; Andrew Gennery
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-16       Impact factor: 3.722

8.  SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.

Authors:  Elie Haddad; Brent R Logan; Linda M Griffith; Rebecca H Buckley; Roberta E Parrott; Susan E Prockop; Trudy N Small; Jessica Chaisson; Christopher C Dvorak; Megan Murnane; Neena Kapoor; Hisham Abdel-Azim; Imelda C Hanson; Caridad Martinez; Jack J H Bleesing; Sharat Chandra; Angela R Smith; Matthew E Cavanaugh; Soma Jyonouchi; Kathleen E Sullivan; Lauri Burroughs; Suzanne Skoda-Smith; Ann E Haight; Audrey G Tumlin; Troy C Quigg; Candace Taylor; Blachy J Dávila Saldaña; Michael D Keller; Christine M Seroogy; Kenneth B Desantes; Aleksandra Petrovic; Jennifer W Leiding; David C Shyr; Hélène Decaluwe; Pierre Teira; Alfred P Gillio; Alan P Knutsen; Theodore B Moore; Morris Kletzel; John A Craddock; Victor Aquino; Jeffrey H Davis; Lolie C Yu; Geoffrey D E Cuvelier; Jeffrey J Bednarski; Frederick D Goldman; Elizabeth M Kang; Evan Shereck; Matthew H Porteus; James A Connelly; Thomas A Fleisher; Harry L Malech; William T Shearer; Paul Szabolcs; Monica S Thakar; Mark T Vander Lugt; Jennifer Heimall; Ziyan Yin; Michael A Pulsipher; Sung-Yun Pai; Donald B Kohn; Jennifer M Puck; Morton J Cowan; Richard J O'Reilly; Luigi D Notarangelo
Journal:  Blood       Date:  2018-08-28       Impact factor: 22.113

Review 9.  B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review.

Authors:  Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

10.  Single-center analysis of long-term outcome after hematopoietic cell transplantation in children with congenital severe T cell immunodeficiency.

Authors:  Evelina Mazzolari; Donatella de Martiis; Concetta Forino; Arnalda Lanfranchi; Silvia Giliani; Roberto Marzollo; Paolo Airò; Luisa Imberti; Fulvio Porta; Luigi D Notarangelo
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.